Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 19/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15211670 | 0.86 | ALPL (0.66) | ALPLLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL9954777 | 0.84 | PIK3CD (0.56) | ALPL | |
| SCHEMBL1404407 | 0.84 | ALPL (1.00) | ALPLLMNASMN1; SMN2 | |
| SCHEMBL15212053 | 0.82 | ALPL (1.00) | ALPLLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL15212028 | 0.82 | ALPL (0.74) | ALPLLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL806765 | 0.80 | LMNA (0.53) | ALPLLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL9953524 | 0.80 | SHMT2 (0.54) | ALPLLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15212833 | 0.79 | ALPL (1.00) | ALPLLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL806771 | 0.78 | SHMT2 (0.55) | ALPLLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15212320 | 0.77 | ALPL (0.72) | ALPLLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370333-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370333-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190010126-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute | 2019-01-10 | — | — | US | disclosed |
| US-9884826-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-12-08 | — | — | US | disclosed |
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-12-08 | — | — | US | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2817292-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford-Burnham Medical Research Institute (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370333-B2 | Sulfonamide compounds and uses as TNAP inhibitors | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885LMNA 2082/4885SMN1; SMN2 1367/4885 |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885LMNA 2082/4885SMN1; SMN2 1367/4885 |
| US-20190010126-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885LMNA 2082/4885SMN1; SMN2 1367/4885 |
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885LMNA 2082/4885SMN1; SMN2 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.